Polaryx Therapeutics Inc.
PLYX evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Market Cap:
- $95.2M
- Lead Asset:
- plx-100 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for PLYX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLYX
Polaryx Therapeutics Inc. (PLYX) is a clinical-stage biotechnology company developing small-molecule therapies for lysosomal storage disorders, with its lead candidate PLX-200 advancing toward Phase 2 and Phase 3 trials.
Key risk: Cash runway limited
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 2 catalysts for Polaryx Therapeutics Inc..
Polaryx Therapeutics Inc. (PLYX) is a clinical-stage biotechnology company developing small-molecule therapies for lysosomal storage disorders, with its lead candidate PLX-200 advancing toward Phase 2 and Phase 3 trials.
- Lead product candidate PLX-200 is being advanced through a Phase 2 proof-of-concept basket trial (SOTERIA) expected to initiate in the second half of 2026 [sec_mda · as of 2026-08-13].
- Cash & equivalents of $11.5M as of 2026-06-30 [sec].
- Net income of -$1.4M and shareholders' equity of $10.9M as of 2026-06-30 [sec].
- Accumulated deficit of approximately $103.6 million as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Development programs focus on NCLs, Krabbe disease, Tay-Sachs, Sandhoff diseases, and NPD types A and B [sec_mda · as of 2026-03-24].
What works
- PLX-200 targets multiple lysosomal storage disorders (CLN2, CLN3, Krabbe, Sandhoff) in a single basket trial, potentially broadening its addressable market [sec_mda · as of 2026-08-13].
- The company has a pre-IND submission meeting completed and an IND application submitted for the SOTERIA trial, indicating regulatory engagement [sec_mda · as of 2026-08-13].
- Polaryx is backed by Mstone Partners, which has a track record of strategic exits including a $680M transaction [sec · filed 2026-01-14].
What to weigh
- Cash & equivalents of $11.5M as of 2026-06-30 may be insufficient to fund operations beyond the third quarter of 2026, based on prior estimates [sec_mda · as of 2026-05-15].
- Accumulated deficit of $103.6M as of June 30, 2026, with expectations of significantly increased expenses for the foreseeable future [sec_mda · as of 2026-08-13].
- Net loss of $1.4M in the most recent quarter and no approved products or revenue from product sales [sec].
- The company's cash runway estimate is based on assumptions that may prove incorrect, and capital could be used sooner than expected [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
PLX-200 is the most advanced product candidate, with a Phase 2 basket trial (SOTERIA) expected to start in H2 2026.
“We are advancing PLX-200, our most advanced product candidate, through a Phase 2 proof-of-concept basket trial which we refer to as SOTERIA (PLX-200-600). We expect to initiate this trial in the second half of 2026.”
SEC MD&A · August 13, 2026
Accumulated deficit reached $103.6 million as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of approximately $103.6 million.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2026-11-01 · Phase3_Start: A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease — Initiation of a pivotal Phase 3 trial for PLX-200 in CLN3 disease; watch for enrollment start and regulatory milestones.
- 2026-12-01 · Phase2_Start: An Open-Label, Multicenter, Phase 2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients With Lysosomal Storage Disorders (SOTERIA) — Initiation of the SOTERIA basket trial covering multiple LSDs; watch for initial safety and efficacy data.
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash of $11.5M may not fund operations beyond Q3 2026 based on prior estimates [sec_mda · as of 2026-05-15].
- No approved products — Company has no approved products or revenue from product sales; net loss of $1.4M in latest quarter [sec].
- Clinical trial execution risk — Initiation and results of SOTERIA and Phase 3 CLN3 trials are uncertain and could affect timelines [sec_mda · as of 2026-08-13].
What to watch
- Initiation of the Phase 3 CLN3 trial for PLX-200 expected on 2026-11-01 [catalyst].
- Initiation of the Phase 2 SOTERIA basket trial for PLX-200 expected on 2026-12-01 [catalyst].
- Cash runway and potential need for additional financing beyond Q3 2026 [sec_mda · as of 2026-05-15].
- Regulatory feedback from the FDA on the SOTERIA IND application [sec_mda · as of 2026-08-13].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Polaryx Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Polaryx Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.08 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~19d
1 buy · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$17.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,658,388 | $12.5M |
| geode capital management, llc | 170,673 | $1.3M |
| millennium management llc | 127,525 | $964K |
| vanguard fiduciary trust co | 104,556 | $790K |
| state street corp | 58,104 | $439K |
| blackrock, inc. | 41,012 | $310K |
| northern trust corp | 27,987 | $212K |
| bank of america corp /de/ | 25,881 | $196K |
| goldman sachs group inc | 13,483 | $102K |
| ubs group ag | 13,479 | $102K |
Showing top 10 of 14 institutional holders of Polaryx Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 2.1%
- Days to cover
- 0.2
- Shares short
- 393,306
- Daily short volume (Oct 9, 2026)
- 50.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLYX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Polaryx Therapeutics Inc.?
Polaryx Therapeutics Inc. (PLYX) is a clinical-stage biotechnology company developing small-molecule therapies for lysosomal storage disorders, with its lead candidate PLX-200 advancing toward Phase 2 and Phase 3 trials.
What is Polaryx Therapeutics Inc.'s lead drug candidate?
Polaryx Therapeutics Inc.'s most advanced tracked candidate is plx-100 (Phase 3) for LSDs (specifically CLN2).
What is Polaryx Therapeutics Inc.'s next catalyst?
Polaryx Therapeutics Inc.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease" — expected November 1, 2026.
Who is the CEO of Polaryx Therapeutics Inc.?
Mr. Alex Yang J.D., L.L.M. is the chief executive officer of Polaryx Therapeutics Inc. (PLYX).
Where is Polaryx Therapeutics Inc. headquartered?
Polaryx Therapeutics Inc. (PLYX) is headquartered in Paramus, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.